Brief: Recro Wins $1.5 Mln Contract To Support Clinical Development Of Topical Treatment For Skin Cancer Prevention
26/01/2022 12:41
Jan 26 (Reuters) - Recro Pharma Inc REPH.O :
* RECRO WINS $1.5 MILLION FORMULATION DEVELOPMENT AND CGMP
MANUFACTURING CONTRACT TO SUPPORT CLINICAL DEVELOPMENT OF
TOPICAL TREATMENT FOR SKIN CANCER PREVENTION
Source text for Eikon: ID:nGNX3vrmWt
Further company coverage: REPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Societal CDMO
See all newsBrief: Corerx Inc Completes Acquisition Of Societal CDMO Inc
Societal CDMO Inc reports results for the quarter ended in December - Earnings Summary
Brief: Societal CDMO Inc Received Notice From Nasdaq Stating Co Regained Compliance With Nasdaq Listing Rule 5550(A)(2) On March 14
Brief: Societal Cdmo Enters Into Definitive Agreement To Be Acquired By Corerx, Inc.
Societal CDMO Inc expected to post a loss of 1 cent a share - Earnings Preview